Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

telitacicept

telitacicept is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 2
Pipeline programs 7
News articles 0
Drug details — telitacicept
Class
—
Route
—
Patents
2
Programs
7
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

telitacicept is an FDA-listed pharmaceutical active ingredient.

Key facts

INN telitacicept

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. RC18G006 Phase 3 · Vor Biopharma · Generalized Myasthenia Gravis
  2. Telitacicept Phase 3 · Vor Biopharma · Generalized Myasthenia Gravis
  3. Telitacicept Phase 3 · Vor Biopharma · Systemic Lupus Erythematosus
  4. Telitacicept Phase 3 · Vor Biopharma · Primary Sjogren's Disease
  5. Telitacicept Phase 2 · Chinese Academy of · Connective Tissue Diseases
  6. Telitacicept Phase 2 · First People's Hospital · Systemic Lupus Erythematosus
  7. Efgartigimod + Telitacicept (1-week interval) group Unknown · First People's Hospital · Myasthenia Gravis

Related patents

Browse patents

  1. US 12403200

    Methods and compositions for treating autoimmune diseases

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11975029

    Compositions and methods for inhibition of lineage specific proteins

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is telitacicept?

telitacicept is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.